ACAD
27.99
-2.01
-6.70%
AEMD
5.01
-0.09
-1.76%
APRI
0.474
+0.004
+0.851%
ARNA
1.61
-0.01
-0.62%
ATEC
0.23
0.00
-0.0435%
CNAT
2.66
-0.02
-0.75%
CRXM
0.19
0.00
0.00%
CYTX
0.24
-0.031
-11.3863%
DXCM
61.64
-1.44
-2.28%
GNMK
5.68
-0.02
-0.35%
HALO
9.905
-0.315
-3.082%
ILMN
133.775
+0.125
+0.094%
INNV
0.078
-0.009
-9.8837%
INO
9.6
-0.76
-7.3369%
ISCO
3.65
-0.08
-2.14%
ISIS
57.56
0.00
0.00%
LGND
119.68
-0.22
-0.18%
LPTN
0.225
-0.025
-9.9200%
MBVX
0.63
-0.03
-4.55%
MEIP
1.4
-0.02
-1.41%
MNOV
6.735
-0.105
-1.535%
MRTX
18.9
-1.31
-6.48%
MSTX
0.327
+0.008
+2.508%
NBIX
43.05
-2
-4.44%
NUVA
52.295
+0.135
+0.259%
ONCS
1.71
-0.11
-6.04%
ONVO
2.575
-0.135
-4.982%
OREX
0.426
-0.036
-7.812%
OTIC
13.1
-0.74
-5.35%
QDEL
16.53
-0.39
-2.3056%
RCPT
231.96
0.00
0.00%
RGLS
5.32
-0.12
-2.21%
RMD
55.92
+0.28
+0.50%
SPHS
1.36
-0.05
-3.55%
SRNE
6.72
-0.11
-1.61%
TROV
3.42
-0.33
-8.80%
VICL
0.384
+0.004
+1.053%
VOLC
18
0.00
0.00%
ZGNX
10.03
-0.25
-2.43%
ACAD
27.99
-2.01
-6.70%
AEMD
5.01
-0.09
-1.76%
APRI
0.474
+0.004
+0.851%
ARNA
1.61
-0.01
-0.62%
ATEC
0.23
0.00
-0.0435%
CNAT
2.66
-0.02
-0.75%
CRXM
0.19
0.00
0.00%
CYTX
0.24
-0.031
-11.3863%
DXCM
61.64
-1.44
-2.28%
GNMK
5.68
-0.02
-0.35%
HALO
9.905
-0.315
-3.082%
ILMN
133.775
+0.125
+0.094%
INNV
0.078
-0.009
-9.8837%
INO
9.6
-0.76
-7.3369%
ISCO
3.65
-0.08
-2.14%
ISIS
57.56
0.00
0.00%
LGND
119.68
-0.22
-0.18%
LPTN
0.225
-0.025
-9.9200%
MBVX
0.63
-0.03
-4.55%
MEIP
1.4
-0.02
-1.41%
MNOV
6.735
-0.105
-1.535%
MRTX
18.9
-1.31
-6.48%
MSTX
0.327
+0.008
+2.508%
NBIX
43.05
-2
-4.44%
NUVA
52.295
+0.135
+0.259%
ONCS
1.71
-0.11
-6.04%
ONVO
2.575
-0.135
-4.982%
OREX
0.426
-0.036
-7.812%
OTIC
13.1
-0.74
-5.35%
QDEL
16.53
-0.39
-2.3056%
RCPT
231.96
0.00
0.00%
RGLS
5.32
-0.12
-2.21%
RMD
55.92
+0.28
+0.50%
SPHS
1.36
-0.05
-3.55%
SRNE
6.72
-0.11
-1.61%
TROV
3.42
-0.33
-8.80%
VICL
0.384
+0.004
+1.053%
VOLC
18
0.00
0.00%
ZGNX
10.03
-0.25
-2.43%
Home » Archive by Category

Syndication

DURECT Announces Closing of Public Offering of Common Stock

April 29, 2016 – 9:15 am

CUPERTINO, Calif., April 29, 2016 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 13,800,000 shares of its common stock, offered at a price of $1.25 per share to the public, including 1,800,000 shares purchased by the underwriters pursuant to their option.  All of the shares in the offering were sold by DURECT.  The gross proceeds to DURECT from this offering were approximately $17.3 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by DURECT.

Stifel acted as sole book-running manager for the offering and Laidlaw & Company (UK) Ltd. acted as co-manager. 

Felix Theeuwes, our Chairman and Chief Scientific Officer, and David Hoffmann, one of our directors, purchased an aggregate of 360,000 shares of common stock in the offering, at the public offering price, for an aggregate purchase price of $450,000.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and is effective.  A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov.  When available, copies of the final prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About DURECT Corporation

DURECT is a biopharmaceutical company focused on two areas of active drug development: new therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its Epigenomic Regulator Program.  Its drug development expertise is being applied primarily to the fields of pain management, CNS disorders, acute organ injury and metabolic diseases such as NAFLD/NASH.  DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs.  Late stage development programs of this nature include POSIMIR® (SABER®-Bupivacaine) and REMOXY® (ORADUR®-oxycodone).  DURECT’s Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 development.  DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.

NOTE: POSIMIR®, ORADUR® and SABER® are trademarks of DURECT Corporation. REMOXY, POSIMIR and DUR-928 are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “may,” “should,” “could,” “will,” “would,” and “will be,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause the Company’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the final prospectus supplement, which has been filed with the SEC, and the risk factors incorporated by reference therein from the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. The Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

 

 

SOURCE DURECT Corporation

Entry Level Positions (In AND Outside the lab)

April 29, 2016 – 9:10 am

We have multiple openings for entry level candidates.
Whether you want to be on the bench/inside the lab setting
Techniques may include (but are not limited to): buffers, reagents, solutions, PCR, HPLC, in vivo, in vitro, gel electrophoresis, centr […

Inside Sales Representative (Sorrento Valley)

April 29, 2016 – 9:00 am

At ACON labs, we are making a difference in medical care by offering medical devices for diagnosing a variety of conditions. In addition, we are able to streamline and reduce costs for the physician and/or patient directly.
We are seeking an Inside […

Jr. Mechanical Engineer (Sorrento Valley)

April 29, 2016 – 8:44 am

At ACON labs, we are making a difference in medical care by offering medical devices for diagnosing a variety of conditions. In addition, we are able to streamline and reduce costs for the physician and/or patient directly.
We are seeking a Jr. Mech […

Lab Technician (all shifts)

April 29, 2016 – 8:34 am

BioPhase Solutions specializes in recruiting top talented professionals for San Diego’s Scientific community. We are currently looking for Lab Technicians (all shifts) to work for a leading San Diego biotechnology company.
Lab Technician (all shifts […

Biocept, Inc. Announces Pricing Of $5 Million Public Offering Of Common Stock And Warrants

April 29, 2016 – 5:57 am

SAN DIEGO, April 29, 2016 /PRNewswire/ — Biocept, Inc. (“Biocept”) (Nasdaq: BIOC) today announced that it has priced a registered public offering of an aggregate of approximately 5.0 million shares of common stock at a price to the public of $1.00 per share. Investors will also receive warrants to purchase up to an aggregate of approximately 3.5 million shares of common stock with an exercise price of $1.30 per share.  The warrants are immediately exercisable and have a term of five years. The offering is expected to close on or about May 4, 2016, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co. acted as exclusive placement agent for the offering, and ROTH Capital Partners, LLC provided advisory services in connection with the offering. 

The total gross proceeds of the offering are expected to be approximately $5.0 million. After deducting the placement agent’s commission and other estimated offering expenses payable by Biocept, the net proceeds to Biocept are expected to be approximately $4.4 million.  Biocept intends to use the net proceeds from the offering for working capital and general corporate purposes.

The shares and warrants are being offered pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC). The securities may be offered only by means of a prospectus. The prospectus and a preliminary prospectus supplement related to the offering have been filed with the SEC, and a final prospectus supplement related to the offering will be filed with the SEC, and are available on the SEC’s website located at http://www.sec.gov and may also be obtained from H.C. Wainwright & Co. by emailing placements@hcwco.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Biocept

Biocept is a molecular diagnostics company with commercial tests targeting lung, breast, gastric, colorectal and prostate cancers and melanoma.  The company uses its proprietary liquid biopsy technology to provide physicians with more precise information for treating and monitoring patients with cancer.  The company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes circulating tumor DNA in both circulating tumor cells (CTCs) and in plasma (ctDNA).  For additional information, please visit www.biocept.com.

Cautionary Statement on Forward-Looking Statements

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the completion of the proposed offering, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

Logo – http://photos.prnewswire.com/prnh/20151013/276540LOGO

 

SOURCE Biocept, Inc.

Field Application Scientist, Cell-based assays (East Coast) Job Code:(2016-0120) – ACEA Biosciences, Inc. – San Diego, CA

April 29, 2016 – 1:07 am

We offer opportunities for career development in a fast-paced and growth-oriented global biotechnology company environment. U.S….
From DeviceSpace.com – 29 Apr 2016 08:07:26 GMT
– View all San Diego jobs

Quality Assurance- Document Control – Pharmatek – San Diego, CA

April 28, 2016 – 10:40 pm

Is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries….
From Pharmatek – 29 Apr 2016 05:40:49 GMT
– View all San Diego jobs

Quality Assurance Associate I – Pharmatek – San Diego, CA

April 28, 2016 – 10:40 pm

Is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries….
From Pharmatek – 29 Apr 2016 05:40:36 GMT
– View all San Diego jobs

Quality Assurance Associate- Batch Record Review – Pharmatek – San Diego, CA

April 28, 2016 – 10:40 pm

Is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical and biotechnology industries….
From Pharmatek – 29 Apr 2016 05:40:35 GMT
– View all San Diego jobs